[the_ad id="21475"]
[ad_1]
H.C. Wainwright analyst Emily Bodnar views the post-earnings selloff in shares of Nkarta as a buying opportunity. The updated data for NKX101 for treatment of acute myeloid leukemia are on track for the first half of 2023, the analyst tells investors in a research note. The firm believes Nkarta is in a favorable position as the front-runner in the CAR-NK space, and believes current levels present a favorable entry point as expectations for AML data “appear low.”
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NKTX:
Click Here to Read the Full Original Article at TipRanks Financial Blog…
[ad_2]
[the_ad id="21476"]